BBLG vs. NAOV, SIENQ, AFIB, VRAX, NMRD, AEMD, NMTR, PBLA, HSDT, and BJDX
Should you be buying Bone Biologics stock or one of its competitors? The main competitors of Bone Biologics include NanoVibronix (NAOV), Sientra (SIENQ), Acutus Medical (AFIB), Virax Biolabs Group (VRAX), Nemaura Medical (NMRD), Aethlon Medical (AEMD), 9 Meters Biopharma (NMTR), Panbela Therapeutics (PBLA), Helius Medical Technologies (HSDT), and Bluejay Diagnostics (BJDX). These companies are all part of the "medical" sector.
NanoVibronix (NASDAQ:NAOV) and Bone Biologics (NASDAQ:BBLG) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, community ranking, valuation and institutional ownership.
16.4% of NanoVibronix shares are owned by institutional investors. Comparatively, 34.3% of Bone Biologics shares are owned by institutional investors. 3.6% of NanoVibronix shares are owned by insiders. Comparatively, 13.0% of Bone Biologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
NanoVibronix has higher revenue and earnings than Bone Biologics.
NanoVibronix received 71 more outperform votes than Bone Biologics when rated by MarketBeat users.
In the previous week, NanoVibronix had 1 more articles in the media than Bone Biologics. MarketBeat recorded 4 mentions for NanoVibronix and 3 mentions for Bone Biologics. NanoVibronix's average media sentiment score of 1.46 beat Bone Biologics' score of 0.06 indicating that Bone Biologics is being referred to more favorably in the news media.
NanoVibronix has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Comparatively, Bone Biologics has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500.
Bone Biologics has a net margin of 0.00% compared to Bone Biologics' net margin of -112.35%. Bone Biologics' return on equity of -95.96% beat NanoVibronix's return on equity.
Summary
NanoVibronix beats Bone Biologics on 7 of the 11 factors compared between the two stocks.
Get Bone Biologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BBLG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bone Biologics Competitors List
Related Companies and Tools
